Sequana Medical NV, a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announced data from its North American pivotal POSEIDON study of the alfapump demonstrating ...

Sequana Medical announces data on alfapump® safety and quality of life to be presented at EASL Congress 2024 "alfapump implantation significantly improved quality of life and showed similar safety ...

Ghent, Belgium – 6 June 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid overload in liver disease, heart failure and ...

Sequana Medical announces data on alfapump® safety and quality of life to be presented at EASL Congress 2024 “alfapump implantation significantly improved quality of life and showed similar safety ...